Evidence map›Paper›PMID 20458765›Full record

ArticleWorld journal of gastroenterology2010

Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Li-Hui Wang, Hong Cheng, Fu-Lian Hu, Jiang Li

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Towards EffectiveInternational journal of molecular sciences · 2025
    Review
  5. Detection ofCurrent issues in molecular biology · 2025
    Article
  6. Article
  7. Article
  8. Molecular tools of antibiotic resistance forFrontiers in gastroenterology (Lausanne, Switzerland) · 2024
    Review
  9. Antimicrobial Resistance Molecular Mechanisms ofAntibiotics (Basel, Switzerland) · 2023
    Article
  10. Review
  11. Current status ofPeerJ · 2021
    Article
  12. Article
  13. Antibiotics (Basel, Switzerland) · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Phenotypic and Genotypic Antibiotic Resistance Patterns inFrontiers in cellular and infection microbiology · 2020
    Article
  18. High Prevalence of Antibiotic Resistance in IranianJournal of clinical medicine · 2019
    Article
  19. Article
  20. Point Mutations atThe American journal of tropical medicine and hygiene · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Li-Hui WangDepartment of Gastroenterology, Peking University First Hospital, Beijing 100034, China.
Hong Cheng
Fu-Lian Hu
Jiang Li
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the resistance of Helicobacter pylori (H. pylori) to ciprofloxacin (CIP), levofloxacin (LVX) and moxifloxacin (MOX) in the Beijing area and to elucidate the resistance mechanisms.

methodsSeventy-nine H. pylori clinical strains, isolated from patients who had undergone upper gastrointestinal endoscopy in Peking University First Hospital from 2007 to 2009, were tested for their susceptibility to CIP, LVX and MOX using the E-test method. H. pylori strain 26695 was included in the susceptibility testing as a control strain. According to the minimal inhibitory concentration (MIC) values, a strain was classified as resistant to CIP, LVX or MOX when the MIC was > 1 microg/mL. We amplified by polymerase chain reaction (PCR) and sequenced the quinolone resistance-determining regions of the gyrA and gyrB genes from 29 quinolone-resistant and 16 quinolone-susceptible H. pylori strains selected at random.

resultsIn this study, the resistance rates of H. pylori to CIP, LVX or MOX were 55.7% (44/79), and the primary resistance rates were 26.6% (21/79). Patients with secondary resistance had received LVX in previous eradication treatments, but not MOX or CIP. Forty-five strains, including 29 CIP, LVX or MOX-resistant strains (MIC: 1.5-32 microg/mL) and 16 susceptible strains, were selected randomly from the 79 strains and used in PCR analysis. Among these 45 strains, 27 resistant strains had mutations in the gyrA gene, including 11 strains with mutations corresponding to Asp-91 (MIC: 2-32 microg/mL), one of which also had a mutation corresponding to Val-150, and 16 strains had mutations at Asn-87 (MIC: 4-32 microg/mL), three of which also had mutations corresponding to Arg-140 or Val-150. In addition, Arg-140, Val-150 or Ala-97 mutations were separately detected in three susceptible strains. Analysis of the gyrB gene showed that one strain of low resistance had a mutation corresponding to Ser-457 that coexisted with an Asp-91 mutation. There was a significant difference in the occurrence of mutations in the gyrA gene between CIP, LVX and MOX-resistant and -susceptible strains (P < 0.05), but 2 resistant strains were found to possess no quinolone resistance-determining region mutations.

conclusionResistance is primarily mediated through point mutations in gyrA. Whether other mechanisms are responsible for resistance in strains without mutations in the QRDR should be detected.

Indexed as

Genes, BacterialAdultAnti-Bacterial AgentsBase SequenceChinaDNA, BacterialDNA GyraseDrug Resistance, BacterialFluoroquinolonesHelicobacter InfectionsHelicobacter pyloriHumansMutationAnti-Bacterial AgentsDNA, BacterialDNA GyraseFluoroquinolones

Identifiers

PMID20458765
PMCPMC2868221
OpenAlexW1991018607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.